Elisa Kieback PhD

Dr. Elisa Kieback obtained her degree in Molecular Biology at the University of Heidelberg, Germany. In her early scientific career she worked with Prof. Wolfgang Uckert at the Max-Delbruck-Center in Berlin, Germany where she performed basic research and translational projects in the field of T cell receptor gene engineering and T cell therapy for cancer. In 2015 she joined the group of Prof. Thomas Blankenstein at the MDC where she coordinates the a Phase I clinical trial with TCR-modified T cell in cancer patients. In 2017 she became CEO and co-founder of the MDC spin-off T-Knife, a biotech company dedicated to develop tumor-specific TCRs.